Skip to main content
. 2020 Jun 8;58(1):538–544. doi: 10.1080/13880209.2020.1770808

Figure 4.

Figure 4.

Socheongryongtang completely inhibited the changes of COPD-related cytokines such as TNF-α, IFN-γ and TGF-β by LPS instillation in the respiratory system. (A) Socheongryongtang thoroughly controlled the DNA levels of cytokines such as TNF-α, IFN-γ and TGF-β to a similar extent as Spiriva treatment. (B) Socheongryongtang suppressed the expression level of TNF-α. (C) Socheongryongtang significantly decreased IFN-γ expression, even with 150 mg/kg socheongryongtang treatment, to an extent similar to that by Spiriva treatment. (D) Similar to the change in IFN-γ expression, socheongryongtang effectively down-regulated TGF-β expression. In other words, the TGF-β level in 150 mg/kg socheongryongtang treatment was strongly suppressed. (a) Control; (b) 0.8 mg/kg LPS intranasal instillation; (c) 1 mg/kg Spiriva treatment for five days after LPS instillation; (d) 150 mg/kg socheongryongtang treatment for five days after LPS instillation; (e) 1500 mg/kg socheongryongtang treatment for five days after LPS instillation. Each bar represents the mean ± SD (N = 8). Arrow, positive cells. *p < 0.05 vs. control group; **p < 0.01 vs. control group; $p < 0.05 vs. LPS intranasal instillation group; $$p < 0.01 vs. LPS intranasal instillation group. Magnification, ×200.